ClinicalTrials.gg
WithdrawnNCT03751969Updated Jun 2, 2022

A Study Evaluating the Mass Balance of Micro-dose[14C]HSK3486 Emulsion Injection in Healthy Adults

A Phase 1 interventional study of HSK3486 in Anesthesia and Sedation, sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd. Withdrawn. Open to male participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-02.

Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

Why this study was withdrawn
study canceled

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 49 Years
Sex
Male
01

Study summary

This study is designed to evaluate the mass balance in healthy Chinese male subjects after receiving a single dose of intravenous [14C]HSK3486, so as to assess the overall pharmacokinetics and safety of HSK3486 in humans and provide a reference for reasonable use of this drug.

02

Conditions studied

  • Anesthesia
  • Sedation
03

In context

Lead sponsor

Sichuan Haisco Pharmaceutical Group Co., Ltd is the lead sponsor of 30 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects enrolled in this study are required to meet all of the following:

    1. Healthy Chinese males aged 18-49 years old (inclusive);
    2. Body weight: (BMI) between 19-26 kg/m2 (inclusive); weight should be no less than 50 kg; weight difference between the lightest and the heaviest subjects enrolled should be no more than 10 kg;
    3. Vital signs: blood pressure between 90-140/60-90 mmHg; heart rate or pulse between 60-99 beats/min; body temperature (ear temperature) between 35.5-37.1 °C; respiratory rate between 12-24 breaths/min; blood oxygen saturation when inhaling ≥ 96% (inclusive);
    4. Normal major organ function, e.g. routine blood test, blood biochemistry, routine urinalysis, feces and fecal occult blood test, and blood coagulation are all normal, or abnormal with no clinical significance as judged by the investigators;
    5. Subjects who voluntarily sign the form, able to communicate well with the investigator and complete all trial procedures in accordance with the protocol.

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet any of the following will be excluded:

    1. Subjects with abnormalities during screening in physical examinations, laboratory tests, 12-lead , chest X-ray or airway evaluation, including airway evaluation of a modified Mallampati score of IV; subjects with positive test result for surface antigen, hepatitis B e antigen, antibody, antibody or syphilis antibody;
    2. Medication history: In receipt of any other drug or participated in any drug or medical device clinical trial within 3 months before screening; or in receipt of propofol, other sedative/narcotic drugs and/or opioid analgesics or compounds containing analgesics within 72 hours prior to screening; or in receipt of any prescription drugs, Chinese herbal medicines, over-the-counter drugs or food supplements (such as vitamins and calcium supplements) other than , paracetamol, oral non-steroidal anti-inflammatory drugs, and topical over-the-counter preparations within 2 weeks before screening; subjects can only be enrolled given the condition that the primary investigator (PI) and the sponsor agree that the drug used has no effect on the safety and mass balance results of the trial;
    3. Past and current medical history:

      A Subjects with a history of any severe disease, or concomitant diseases or abnormalities that may affect the test results as judged by the investigator, including but not limited to diseases or abnormalities in the circulatory system, endocrine system, neurological system, digestive system, urinary system, hematologic system, immune system, mental and metabolic aspects; B Subjects who have a past or current history of cardiovascular disease, including: heart failure, ischemic heart disease, long syndrome, arrhythmia requiring medication; a family history of Adams-Stokes syndrome or long QT syndrome; QTcF interval ≥ 450 ms (corrected by Fridericia's formula); C Subjects who have a past or current history of respiratory disease, including: obstructive pulmonary disease, asthma, or a history of bronchospasm requiring treatment within 3 months prior to screening; acute respiratory infections within 1 week prior to screening, with significant fever, wheezing, nasal congestion, and coughing.

      D Subjects who have a past or current history of gastrointestinal disease, including: gastroesophageal reflux, hemorrhoids or perianal disease with fecal blood, habitual constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease, etc.; E Subjects who have major surgery within 6 months before screening, or surgical incision not completely healed. Major surgery includes, but is not limited to any surgery that has a significant risk of bleeding, prolonged general anesthesia, incisional or significant traumatic injury; F Subjects with hyperactive immune response, including: sensitive to of HSK3486 emulsion injections (soybean oil, glycerin, triglyceride, egg lecithin, sodium oleate and sodium hydroxide), history of drug allergies (including anesthetics), or other allergic diseases (such as allergic to any food ingredient or have special dietary requirements and cannot follow a uniform diet);

    4. Alcohol abuse or history of alcohol abuse within 3 months prior to screening, e.g. > 14 units of alcohol consumption per week (1 unit = 360 mL beer or 45 mL liquor with 40% alcohol or 150 mL wine), or positive result for breath alcohol test at screening;
    5. Consumption of more than 5 cigarettes daily within 3 months before screening or habitual use of nicotine-containing products which cannot be withdrawn during the trial; history of respiratory irritation symptoms caused by smoking;
    6. Chronic drug abuse or use of soft drugs (such as marijuana) within 3 months before screening; or use of hard drugs (such as cocaine, amphetamines, phencyclidine) within 1 year before screening; or any signs of chronic benzodiazepines use (such as insomnia, anxiety) or positive urine drug test during screening;
    7. Habitual consumption of grapefruit juice or excessive tea, coffee and/or caffeinated beverages which cannot be withdrawn during the trial;
    8. Engaged in work requiring long-term exposure to radioactive conditions; or significant radioactive exposure within 1 year prior to the trial (≥ 2 chest/abdominal CT, or ≥ 3 other types of X-ray tests); or those who have participated in radiolabelling testing;
    9. Fertility planner during the trial period and within 1 year after the completion of the trial, or subjects or their spouses who refuse to take strict contraceptive measures (including taking condom, contraceptive sponge, contraceptive gel, diaphragm, intrauterine devices, oral or injectable contraceptives, subcutaneous implants, etc.) during the trial and within 1 year after the completion of the trial;
    10. Subjects who received blood transfusion within 1 month before screening or who had blood loss or blood donation ≥ 200 mL, or subjects who had plasma donation or plasma exchange within 7 days before the trial;
    11. Subject deemed unsuitable by the investigator for any other reason
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    HSK3486

    0.4 mg/kg of HSK3486 emulsion injection (containing \[14C\] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg) .

    Drug: HSK3486

Interventions

  • The first 2 subjects will receive an intravenous injection of 0.4 mg/kg of HSK3486 emulsion injection (containing \[14C\] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg, i.e. a subject with the body weight of 60 kg is administered with a radiation dose of 300 nCi). The radiation dose for subsequent subjects can be adjusted based on the results of the first 2 subjects.

06

What researchers measure

Primary outcomes

  1. Percentage of cumulative drug excretion of [14C]HSK3486 on biological specimens(urine and faeces) accounting for total radiation drug dose

    Though collecting different periods of biological specimens(urine and faeces) , detecting their respective drug excretion of \[14C\]HSK3486,calculating the total cumulative excretion amount and relevant proportion of each kind of specimen(urine or faeces).

    Time frame: from the start of administration to 96 hours after administration

  2. Maximum Plasma Concentration [Cmax] of 14C radioactivity and non-radiolabeled HSK3486 respectively

    Pharmacokinetic Measures

    Time frame: from the start of administration to 96 hours after administration

  3. Time to plasma peak concentration[Tmax] of 14C radioactivity and non-radiolabeled HSK3486 respectively

    Pharmacokinetic Measures

    Time frame: from the start of administration to 96 hours after administration

  4. Clearance half-life[t1/2] of 14C radioactivity and non-radiolabeled HSK3486 respectively

    Pharmacokinetic Measures

    Time frame: from the start of administration to 96 hours after administration

  5. Area Under the Curve [AUC] of 14C radioactivity and non-radiolabeled HSK3486 respectively

    Pharmacokinetic Measures

    Time frame: from the start of administration to 96 hours after administration

Secondary outcomes

  1. Number of patients with adverse events and serious adverse events

    Safety Measures

    Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)

  2. Blood routine test

    Observe the changes of blood routine test during the whole trial

    Time frame: At the time of subject is being screened and at the end of study( nearly 96h after drug administration)

  3. Urine routine test

    Observe the changes of urine routine test during the whole trial

    Time frame: At the time of subject is being screened and at the end of study( nearly 96h after drug administration)

  4. Blood biochemical examination

    Observe the changes of Blood biochemical examination during the whole trial

    Time frame: At the time of subject is being screened and at the end of study( nearly 96h after drug administration)

  5. Blood pressure

    Observe the changes of blood pressure during the whole trial

    Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)

  6. Heart rate or pulse

    Observe the changes of heart rate or pulse during the whole trial

    Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)

  7. Respiratory rate or blood oxygen saturation

    Observe the changes of respiratory rate or blood oxygen saturation during the whole trial

    Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)

  8. Heart rate of electrocardiogram

    Observe the changes of heart rate of electrocardiogram during the whole trial

    Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)

  9. RR interval of electrocardiogram

    Observe the changes of RR interval of electrocardiogram during the whole trial

    Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)

  10. QT interval of electrocardiogram

    Observe the changes of QT interval of electrocardiogram during the whole trial

    Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)

  11. QTcF interval of electrocardiogram

    Observe the changes of QTcF interval of electrocardiogram during the whole trial

    Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)

  12. PR interval of electrocardiogram

    Observe the changes of PR interval of electrocardiogram during the whole trial

    Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)

  13. QRS interval of electrocardiogram

    Observe the changes of QRS interval of electrocardiogram during the whole trial

    Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Nov 2020, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2018
First posted
Nov 23, 2018
StartActual
Mar 30, 2020
Primary completionActual
Nov 1, 2020
CompletionActual
Dec 1, 2020
Last update
Jun 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03751969
Responsible party
Sponsor
First posted
Nov 23, 2018
Start date
Mar 30, 2020
Primary completion
Nov 1, 2020
Completion
Dec 1, 2020
Last update
Jun 2, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion